GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma

• Status: Unknown status
• Trial end date: 2021-03-30
• Target enrollment: 0
• Participant gender: All

Summary

This study is to explore the efficacy and safety of GLIDE regiment in patients with aggressive NK/T cell lymphoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sichuan University
• Treatments: BB 1101; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Etoposide; Etoposide phosphate; Gemcitabine; Ifosfamide; Isophosphamide mustard

Criteria

Inclusion Criteria:

1. diagnosis of ENKL defined by World Health Organization classification 2008;

2. age above 18 years;

3. Eastern Cooperative Oncology Group performance status of 0-3;

4. adequate organ function defined as: total bilirubin≤2 times the upper limit of normal; alanine aminotransferase and aspartate aminotransferase levels≤2.5 times the upper limit of normal; serum creatinine≤1.5 mg/dL; creatinine clearance ≥50 mL/minute and normal electrocardiogram results.

Exclusion Criteria:

1. uncontrolled infection;

2. pregnant or lactating women;

3. contraindication to one of the trial drugs (eg. anaphylaxis to L-asparaginase);

4. any coexisting medical problems of sufficient severity to prevent full compliance with the study protocol